BeStock  
Stocks › Biotechnology › PTGX

Protagonist Therapeutics PTGX

US equityMarket cap rank #1605Biotechnology
$121.40 −$2.62 (-2.11%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $121.40 0.00%
Open$123.41
Prev close$124.02
Day range$120.15 – $125.91
Volume600.7K
Market cap$7.92B
P/E (TTM)25.7
Dividend yield–

PTGX Stock News

Headlines matching Protagonist Therapeutics or the PTGX ticker, most recent first.

  • Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy RatingMarket news · 2 Sep 2026 · Direct mention
  • Protagonist Therapeutics(PTGX.US) Officer Sells US$18.24 Million in Common StockMarket news · 11 Sep 2026 · Direct mention
  • Citi Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $182Market news · 10 Sep 2026 · Direct mention
  • A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $149 to $182Market news · 1 Sep 2026 · Direct mention
  • J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $149Market news · 1 Sep 2026 · Direct mention
  • H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $170Market news · 1 Sep 2026 · Direct mention
  • Goldman Sachs Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $186Market news · 1 Sep 2026 · Direct mention
  • A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $153 to $175Market news · 7 Aug 2026 · Direct mention
  • H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $170 PositiveMarket news · 31 Aug 2026 · Direct mention
  • Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $173Market news · 31 Aug 2026 · Direct mention
  • BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $178Market news · 31 Aug 2026 · Direct mention
  • BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $178 PositiveMarket news · 17 Aug 2026 · Direct mention
  • J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $149 PositiveMarket news · 13 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $167 to $186Market news · 11 Aug 2026 · Direct mention
  • Goldman Sachs Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Raises Target Price to $186 PositiveMarket news · 10 Aug 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on PTGX.

Sign in to join the discussion.

Scroll to Top